創薬における人工知能市場：提供、技術、プロセス、用途、治療領域、エンドユーザー別-2025-2030年世界予測

創薬における人工知能市場の2023年の市場規模は10億8,000万米ドルで、2024年には13億5,000万米ドルに達すると予測され、CAGR 27.10％で成長し、2030年には58億1,000万米ドルに達すると予測されています。

創薬における人工知能（AI）は、高度な計算技術を分子設計と検証プロセスに統合することで、医薬品の研究開発に変革をもたらすものです。この分野におけるAIの範囲は、有望な分子標的の同定から仮想スクリーニングの促進、さらには生体系における薬物の挙動予測に至るまで、あらゆる段階に及ぶ。その必要性は、時間がかかり、高い失敗率を伴う従来の方法を合理化する業界の緊急の必要性から生じています。AIの応用は、ゲノム研究、個別化医療、合成スクリーニング・プロセスの最適化など、さまざまな領域に及ぶ。最終用途分野には製薬会社、バイオテクノロジー企業、研究開発受託機関などがあり、AIを活用してコスト削減と医薬品開発パイプラインの有効性向上を図っています。市場成長は、技術的進歩、AI企業と製薬企業とのパートナーシップの増加、精密医療に対する需要の高まりに大きく影響されています。主な機会は、機械学習アルゴリズムの継続的な発展、膨大な生物医学データへのアクセス、医療技術の革新に対する政府の支援から生じる。こうした機会を捉えるために、企業は予測分析を強化し、リアルタイムのデータ分析を容易にする堅牢なAIプラットフォームの開発に投資すべきです。しかし、課題は依然として残っています。規制上のハードル、データプライバシーに関する懸念、大規模な注釈付きデータセットの必要性などが、創薬におけるAIの統合を複雑にしています。明確なイノベーションの道筋は、AIと従来の手法を組み合わせたハイブリッド・アプローチや、計算生物学を発展させる学際的コラボレーションにあります。今後の注目分野としては、AIを活用した薬剤の再利用や新規化合物ライブラリーの開発などが挙げられます。市場の性質は非常にダイナミックであり、急速な技術進歩や高度なコラボレーションの動向が見られます。俊敏性を維持し、戦略的パートナーシップを育むことで、利害関係者は市場の抑制要因を克服し、医薬品開発におけるAIの関連性の高まりを活用することができます。

市場力学：急速に進化する創薬における人工知能市場の主要市場インサイトを公開

創薬における人工知能市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 創薬プロセスの管理とコスト削減の要求
  • 前臨床試験中に生成される膨大なデータを管理する必要性の高まり
  • バイオ医薬品企業全体での採用の増加
• 市場抑制要因
  • 熟練した専門家の不足
• 市場機会
  • AIクラウドによる創薬の合理化・自動化アプローチ
  • 研究開発投資の増加
• 市場の課題
  • データセットの限られた利用可能性

ポーターのファイブフォース：創薬における人工知能市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：創薬における人工知能市場における外部からの影響の把握

外部マクロ環境要因は、創薬における人工知能市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析創薬における人工知能市場における競合情勢の把握

創薬における人工知能市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス創薬における人工知能市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、創薬における人工知能市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨創薬における人工知能市場における成功への道筋を描く

創薬における人工知能市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 創薬プロセスの制御とコスト削減の需要
    • 前臨床研究中に生成される大量のデータを管理する必要性の高まり
    • バイオ医薬品企業での導入拡大
  • 抑制要因
    • 熟練した専門家の不足
  • 機会
    • AIクラウドが創薬における合理化と自動化のアプローチを実現
    • 増加する研究開発投資
  • 課題
    • データセットの入手が制限される
• 市場セグメンテーション分析
  • 提供内容：AIソフトウェアが創薬への革新的なアプローチを提案
  • テクノロジー：パーソナライズされた治療におけるコンテキスト認識処理の採用拡大
  • プロセス：計算能力と予測能力による創薬プロセスの大幅な強化
  • 応用：ヒト臨床試験におけるAI設計の低分子医薬品の使用が増加しています。
  • 治療領域：個別化がん治療のための創薬におけるAIの採用が増加。
  • エンドユーザー：製薬企業やバイオテクノロジー企業による創薬プロセスの加速化を目的とした創薬におけるAIの利用増加
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 創薬における人工知能市場：提供別

• サービス
• ソフトウェア

第7章 創薬における人工知能市場：技術別

• コンテキスト認識処理
• 機械学習
• 自然言語処理

第8章 創薬における人工知能市場：プロセス別

• 候補者の選定と検証
• ヒットの識別と優先順位付け
• ヒット・トゥ・リードの特定/リード生成
• リード最適化
• ターゲットの特定と選択
• ターゲット検証

第9章 創薬における人工知能市場：用途別

• 生物製剤の設計と最適化
• 病気の特定と評価
• 安全性、毒性、コンプライアンス評価
• 低分子設計と最適化
• ワクチンの設計と最適化

第10章 創薬における人工知能市場治療領域別

• 心血管疾患
• 免疫腫瘍学
• 代謝性疾患
• 神経変性疾患

第11章 創薬における人工知能市場：エンドユーザー別

• 契約調査機関
• 製薬・バイオテクノロジー企業
• 研究センターおよび学術・政府機関

第12章 南北アメリカの創薬における人工知能市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第13章 アジア太平洋地域の創薬における人工知能市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第14章 欧州・中東・アフリカの創薬における人工知能市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第15章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • メルク、AIを活用した創薬を強化するため2つの戦略的提携を締結
  • インシリコのフェーズ IIプログラムの開始は、ジェネレーティブ AIの勢いを浮き彫りにする
  • Google Cloud、AIを活用した創薬と精密医療を安全に加速するソリューションを発表
• 戦略分析と提言

企業一覧

• Aria Pharmaceuticals, Inc.
• Atomwise, Inc.
• BenevolentAI Limited
• BenevolentAI SA
• BioSymetrics Inc.
• BPGbio Inc.
• Butterfly Network, Inc.
• Cloud Pharmaceuticals, Inc.
• Cyclica Inc.
• Deargen Inc.
• Deep Genomics Incorporated
• Envisagenics, Inc.
• Euretos Services BV
• Exscientia PLC
• Insilico Medicine
• Insitro, Inc.
• International Business Machines Corporation
• InveniAI LLC
• Microsoft Corporation
• Novartis AG
• NVIDIA Corporation
• Oracle Corporation
• Owkin, Inc.
• Verge Genomics Inc.
• XtalPi Inc.

LIST OF FIGURES

• FIGURE 1. ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET RESEARCH PROCESS
• FIGURE 2. ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 17. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 21. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 26. ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 27. ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET DYNAMICS
• TABLE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CONTEXT-AWARE PROCESSING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY MACHINE LEARNING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CANDIDATE SELECTION & VALIDATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION & PRIORITIZATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT-TO-LEAD IDENTIFICATION/ LEAD GENERATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION & SELECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TARGET VALIDATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS DESIGN & OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DISEASE IDENTIFICATION & ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY SAFETY, TOXICITY, & COMPLIANCE ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULE DESIGN & OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY VACCINE DESIGN & OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY IMMUNO-ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY METABOLIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. ARGENTINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 48. ARGENTINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 49. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 50. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 51. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 54. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 55. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 56. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 57. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 58. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 60. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 61. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 62. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 63. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 64. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 66. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 67. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 68. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 69. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 70. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 72. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 73. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 74. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 76. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 77. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 78. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 79. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 80. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 81. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 82. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 83. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 84. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 85. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 86. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 87. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 88. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 89. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 90. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 92. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 93. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 94. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 95. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 96. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 98. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 99. INDONESIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 100. INDONESIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 101. INDONESIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 102. INDONESIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 103. INDONESIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 104. INDONESIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 105. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 106. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 107. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 108. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 110. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 111. MALAYSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 112. MALAYSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 113. MALAYSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 114. MALAYSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 115. MALAYSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 116. MALAYSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 117. PHILIPPINES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 118. PHILIPPINES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 119. PHILIPPINES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 120. PHILIPPINES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 121. PHILIPPINES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 122. PHILIPPINES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 123. SINGAPORE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 124. SINGAPORE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 125. SINGAPORE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 126. SINGAPORE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 127. SINGAPORE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 128. SINGAPORE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 132. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 134. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 135. TAIWAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 136. TAIWAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 137. TAIWAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 138. TAIWAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 139. TAIWAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 140. TAIWAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 141. THAILAND ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 142. THAILAND ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 143. THAILAND ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 144. THAILAND ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. THAILAND ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 146. THAILAND ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 147. VIETNAM ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 148. VIETNAM ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 149. VIETNAM ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 150. VIETNAM ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 151. VIETNAM ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 152. VIETNAM ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 157. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 158. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 159. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 160. DENMARK ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 161. DENMARK ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 162. DENMARK ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 163. DENMARK ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 164. DENMARK ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 165. DENMARK ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 166. EGYPT ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 167. EGYPT ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 168. EGYPT ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 169. EGYPT ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 170. EGYPT ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 171. EGYPT ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 172. FINLAND ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 173. FINLAND ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 174. FINLAND ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 175. FINLAND ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 176. FINLAND ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 177. FINLAND ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 178. FRANCE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 179. FRANCE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 180. FRANCE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 181. FRANCE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 182. FRANCE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 183. FRANCE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 184. GERMANY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 185. GERMANY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 186. GERMANY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 187. GERMANY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 188. GERMANY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 189. GERMANY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 190. ISRAEL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 191. ISRAEL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 192. ISRAEL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 193. ISRAEL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 194. ISRAEL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 195. ISRAEL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 196. ITALY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 197. ITALY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 198. ITALY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 199. ITALY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 200. ITALY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 201. ITALY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 202. NETHERLANDS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 203. NETHERLANDS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 204. NETHERLANDS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 205. NETHERLANDS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 206. NETHERLANDS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 207. NETHERLANDS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 208. NIGERIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 209. NIGERIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 210. NIGERIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 211. NIGERIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 212. NIGERIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 213. NIGERIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 214. NORWAY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 215. NORWAY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 216. NORWAY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 217. NORWAY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 218. NORWAY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 219. NORWAY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 220. POLAND ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 221. POLAND ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 222. POLAND ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 223. POLAND ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 224. POLAND ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 225. POLAND ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 226. QATAR ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 227. QATAR ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 228. QATAR ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 229. QATAR ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 230. QATAR ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 231. QATAR ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 232. RUSSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 233. RUSSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 234. RUSSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 235. RUSSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 236. RUSSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 237. RUSSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 238. SAUDI ARABIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 239. SAUDI ARABIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 240. SAUDI ARABIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 241. SAUDI ARABIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 242. SAUDI ARABIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 243. SAUDI ARABIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 244. SOUTH AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 245. SOUTH AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 246. SOUTH AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 247. SOUTH AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 248. SOUTH AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 249. SOUTH AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 250. SPAIN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 251. SPAIN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 252. SPAIN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 253. SPAIN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 254. SPAIN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 255. SPAIN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 256. SWEDEN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 257. SWEDEN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 258. SWEDEN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 259. SWEDEN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 260. SWEDEN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 261. SWEDEN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 262. SWITZERLAND ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 263. SWITZERLAND ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 264. SWITZERLAND ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 265. SWITZERLAND ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 266. SWITZERLAND ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 267. SWITZERLAND ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 268. TURKEY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 269. TURKEY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 270. TURKEY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 271. TURKEY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 272. TURKEY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 273. TURKEY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 274. UNITED ARAB EMIRATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 275. UNITED ARAB EMIRATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 276. UNITED ARAB EMIRATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 277. UNITED ARAB EMIRATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 278. UNITED ARAB EMIRATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 279. UNITED ARAB EMIRATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 280. UNITED KINGDOM ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 281. UNITED KINGDOM ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 282. UNITED KINGDOM ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 283. UNITED KINGDOM ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 284. UNITED KINGDOM ARTIFI

The Artificial Intelligence in Drug Discovery Market was valued at USD 1.08 billion in 2023, expected to reach USD 1.35 billion in 2024, and is projected to grow at a CAGR of 27.10%, to USD 5.81 billion by 2030.

Artificial Intelligence (AI) in drug discovery is a transformative facet of pharmaceutical research and development, integrating advanced computational techniques into the molecule design and validation process. The scope of AI in this field encompasses all stages from identifying promising molecular targets to facilitating virtual screening and even predicting drug behavior in biological systems. Its necessity stems from the industry's urgent need to streamline traditional methods that are time-consuming and fraught with high failure rates. The application of AI spans various domains such as genomics research, personalized medicine, and optimization of synthetic screening processes. End-use sectors include pharmaceuticals, biotechnology firms, and contract research organizations, which leverage AI to reduce costs and improve the efficacy of drug development pipelines. Market growth is significantly influenced by technological advancements, increasing partnerships between AI firms and pharmaceutical companies, and escalating demand for precision medicine. Key opportunities arise from ongoing developments in machine learning algorithms, access to vast biomedical data, and governmental support for innovation in health technology. To seize these opportunities, companies should invest in developing robust AI platforms that enhance predictive analytics and facilitate real-time data analysis. However, challenges persist; regulatory hurdles, data privacy concerns, and the need for large, annotated datasets complicate the integration of AI in drug discovery. A well-defined innovation pathway lies in hybrid approaches that combine AI with traditional methods and interdisciplinary collaborations that advance computational biology. Future areas of interest include AI-driven drug repurposing and development of novel compound libraries. The nature of the market is highly dynamic, with rapid technological advancements and a trend towards high collaboration. Remaining agile and fostering strategic partnerships will enable stakeholders to overcome market limitations and capitalize on the increasing relevance of AI in pharmaceutical development.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Artificial Intelligence in Drug Discovery Market

The Artificial Intelligence in Drug Discovery Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Demand to Control Drug Discovery Process and Reduce Cost
  • Increasing Need to Manage the Large Data Generated During Preclinical Studies
  • Increasing Adoption across Biopharmaceutical Companies
• Market Restraints
  • Unavailability of Skilled Professionals
• Market Opportunities
  • AI Cloud to Create a Streamlined and Automated Approach in Drug Discovery
  • Increasingly Growing R&D Investments
• Market Challenges
  • Limited Availability of Data Sets

Porter's Five Forces: A Strategic Tool for Navigating the Artificial Intelligence in Drug Discovery Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Artificial Intelligence in Drug Discovery Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Artificial Intelligence in Drug Discovery Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Artificial Intelligence in Drug Discovery Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Artificial Intelligence in Drug Discovery Market

A detailed market share analysis in the Artificial Intelligence in Drug Discovery Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Artificial Intelligence in Drug Discovery Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Artificial Intelligence in Drug Discovery Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Artificial Intelligence in Drug Discovery Market

A strategic analysis of the Artificial Intelligence in Drug Discovery Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Artificial Intelligence in Drug Discovery Market, highlighting leading vendors and their innovative profiles. These include Aria Pharmaceuticals, Inc., Atomwise, Inc., BenevolentAI Limited, BenevolentAI SA, BioSymetrics Inc., BPGbio Inc., Butterfly Network, Inc., Cloud Pharmaceuticals, Inc., Cyclica Inc., Deargen Inc., Deep Genomics Incorporated, Envisagenics, Inc., Euretos Services BV, Exscientia PLC, Insilico Medicine, Insitro, Inc., International Business Machines Corporation, InveniAI LLC, Microsoft Corporation, Novartis AG, NVIDIA Corporation, Oracle Corporation, Owkin, Inc., Verge Genomics Inc., and XtalPi Inc..

Market Segmentation & Coverage

This research report categorizes the Artificial Intelligence in Drug Discovery Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Offering, market is studied across Services and Software.
• Based on Technology, market is studied across Context-Aware Processing, Machine Learning, and Natural Language Processing.
• Based on Process, market is studied across Candidate Selection & Validation, Hit Identification & Prioritization, Hit-to-lead Identification/ Lead generation, Lead Optimization, Target Identification & Selection, and Target Validation.
• Based on Application, market is studied across Biologics Design & Optimization, Disease Identification & Assessment, Safety, Toxicity, & Compliance Assessment, Small Molecule Design & Optimization, and Vaccine Design & Optimization.
• Based on Therapeutic Area, market is studied across Cardiovascular Disease, Immuno-Oncology, Metabolic Diseases, and Neurodegenerative Diseases.
• Based on End User, market is studied across Contract Research Organizations, Pharmaceutical & Biotechnology Companies, and Research Centers and Academic & Government Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Demand to Control Drug Discovery Process and Reduce Cost
    • 5.1.1.2. Increasing Need to Manage the Large Data Generated During Preclinical Studies
    • 5.1.1.3. Increasing Adoption across Biopharmaceutical Companies
  • 5.1.2. Restraints
    • 5.1.2.1. Unavailability of Skilled Professionals
  • 5.1.3. Opportunities
    • 5.1.3.1. AI Cloud to Create a Streamlined and Automated Approach in Drug Discovery
    • 5.1.3.2. Increasingly Growing R&D Investments
  • 5.1.4. Challenges
    • 5.1.4.1. Limited Availability of Data Sets
• 5.2. Market Segmentation Analysis
  • 5.2.1. Offering: AI Software propose a revolutionary approach to drug discovery
  • 5.2.2. Technology: Growing adoption of context-aware processing in personalized therapeutic
  • 5.2.3. Process: Significant augmentation in the drug discovery process with computational prowess and predictive capabilities
  • 5.2.4. Application: Growing usage of AI-designed small molecule drugs for human clinical trials.
  • 5.2.5. Therapeutic Area: Rising adoption of AI in the drug discovery for personalized cancer treatment.
  • 5.2.6. End User: Increasing use of AI in the drug discovery by pharmaceutical and biotechnology companies to accelerate their drug discovery process
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Artificial Intelligence in Drug Discovery Market, by Offering

• 6.1. Introduction
• 6.2. Services
• 6.3. Software

7. Artificial Intelligence in Drug Discovery Market, by Technology

• 7.1. Introduction
• 7.2. Context-Aware Processing
• 7.3. Machine Learning
• 7.4. Natural Language Processing

8. Artificial Intelligence in Drug Discovery Market, by Process

• 8.1. Introduction
• 8.2. Candidate Selection & Validation
• 8.3. Hit Identification & Prioritization
• 8.4. Hit-to-lead Identification/ Lead generation
• 8.5. Lead Optimization
• 8.6. Target Identification & Selection
• 8.7. Target Validation

9. Artificial Intelligence in Drug Discovery Market, by Application

• 9.1. Introduction
• 9.2. Biologics Design & Optimization
• 9.3. Disease Identification & Assessment
• 9.4. Safety, Toxicity, & Compliance Assessment
• 9.5. Small Molecule Design & Optimization
• 9.6. Vaccine Design & Optimization

10. Artificial Intelligence in Drug Discovery Market, by Therapeutic Area

• 10.1. Introduction
• 10.2. Cardiovascular Disease
• 10.3. Immuno-Oncology
• 10.4. Metabolic Diseases
• 10.5. Neurodegenerative Diseases

11. Artificial Intelligence in Drug Discovery Market, by End User

• 11.1. Introduction
• 11.2. Contract Research Organizations
• 11.3. Pharmaceutical & Biotechnology Companies
• 11.4. Research Centers and Academic & Government Institutes

12. Americas Artificial Intelligence in Drug Discovery Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Artificial Intelligence in Drug Discovery Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Artificial Intelligence in Drug Discovery Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2023
• 15.2. FPNV Positioning Matrix, 2023
• 15.3. Competitive Scenario Analysis
  • 15.3.1. Merck Enters Two Strategic Collaborations to Strengthen AI-driven Drug Discovery
  • 15.3.2. Launch of Insilico's Phase II Program Highlights Generative AI Momentum
  • 15.3.3. Google Cloud Launches AI-powered Solutions to Safely Accelerate Drug Discovery and Precision Medicine
• 15.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Aria Pharmaceuticals, Inc.
• 2. Atomwise, Inc.
• 3. BenevolentAI Limited
• 4. BenevolentAI SA
• 5. BioSymetrics Inc.
• 6. BPGbio Inc.
• 7. Butterfly Network, Inc.
• 8. Cloud Pharmaceuticals, Inc.
• 9. Cyclica Inc.
• 10. Deargen Inc.
• 11. Deep Genomics Incorporated
• 12. Envisagenics, Inc.
• 13. Euretos Services BV
• 14. Exscientia PLC
• 15. Insilico Medicine
• 16. Insitro, Inc.
• 17. International Business Machines Corporation
• 18. InveniAI LLC
• 19. Microsoft Corporation
• 20. Novartis AG
• 21. NVIDIA Corporation
• 22. Oracle Corporation
• 23. Owkin, Inc.
• 24. Verge Genomics Inc.
• 25. XtalPi Inc.